StreetInsider.com News Articles

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 -0500

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

Fri, 10 Jan 2025 04:00:00 -0500

SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA) granted Breakthrough Therapy Designation for Carteyva^® (relmacabtagene autoleucel injection) as second-line treatment in adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) . Carteyva^®is an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product independently developed by JW Therapeutics.

The Breakthrough

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

Fri, 10 Jan 2025 04:00:00 -0500

The Breakthrough

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

Fri, 10 Jan 2025 04:00:00 -0500

The Breakthrough

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

Fri, 10 Jan 2025 04:00:00 -0500

The Breakthrough

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

Fri, 10 Jan 2025 04:00:00 -0500

The Breakthrough

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

Fri, 10 Jan 2025 04:00:00 -0500

The Breakthrough

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

Fri, 10 Jan 2025 04:00:00 -0500

The Breakthrough

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

Fri, 10 Jan 2025 04:00:00 -0500

The Breakthrough

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

Tue, 27 Aug 2024 05:00:00 -0500

SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has approved the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva^® (relmacabtagene autoleucel injection) for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma (r/r MCL). This is the third marketing approval on Carteyva^® submitted by JW Therapeutics, and is the first cell therapy

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

Tue, 27 Aug 2024 05:00:00 -0500

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

Tue, 27 Aug 2024 05:00:00 -0500